SFVAMC study explains prostate cancer resistance to hormone therapy

Hormone therapy is often used to treat prostate cancer, but these drugs that mimic the effects of estrogen do not work on many late-stage cancers. Now San Francisco Veterans Affairs Medical Center researchers say they can explain the failure of these drugs, and suggest a way to restore their potency.

The study, published in the latest issue of Journal of the National Cancer Institute, reveals that late-stage prostate cancer is unresponsive to hormone therapy because the cells have shut down genes for the estrogen receptors where the drugs act.

The genes are switched off by a process called hypermethylation, a well-known process in which numerous methyl groups are attached to the regulatory stretches of DNA near the beginning of the gene, said the studys lead author Raj Dahiya, PhD, director of the urology research center at SFVAMC, and UCSF professor of urology.

This hypermethylation explains why we see inactivation of estrogen receptors in prostate cancer, and why hormone therapy no longer works in many cases, said Dahiya, whose research was supported by funding from the Department of Veterans Affairs, and by grants from the National Institutes of Health, which were managed by Northern California Institute for Research and Education (NCIRE).

In their study, Dahiyas group first showed that normal prostate cells were free of methylation at estrogen receptor genes and the cells displayed plenty of estrogen receptors. However, cells from late-stage prostate cancers had hypermethylation on their estrogen receptor genes and the cells displayed no estrogen receptors. Cells from an early stage prostate cancer have some methylation, which leads to intermediate activity, and the generation of relatively few estrogen receptors, Dahiya said.

Studies of prostate tissue taken from 38 prostate cancer patients further strengthened the link between hypermethylation and prostate cancer. The researchers found that nearly all tissue samp

Contact: Kevin Boyd
University of California - San Francisco

Page: 1 2

Related biology news :

1. SFVAMC study may revive old approach to high blood pressure therapy
2. Brain damage from HIV, Alzheimers, may have similar mechanism, SFVAMC researchers say
3. The skins acid coating: SFVAMC researchers explain its origin and how it maintains skin integrity
4. Some women may have gene sequence that reduces breast cancer risk, SFVAMC study finds
5. SFVAMC/UCSF researchers develop lead for a new Alzheimers disease drug - a fragment of a brain growth protein
6. SFVAMC-UCSF scientists solve a key protein structure
7. Student science contest participation influences study, career choices, alumni say
8. New study shows hope for treating inhalant abuse
9. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
10. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
11. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia

Post Your Comments:

(Date:5/28/2020)... ... 27, 2020 , ... CrucialTrak, a global designer and manufacturer of biometric access ... (CEG) to market and sell its complete line of biometric readers and access ... infrastructure optimization solutions . , Brett Mason, CrucialTrak’s Director of Channel Sales for ...
(Date:5/28/2020)... ... May 28, 2020 , ... Actuate Therapeutics, ... their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) will be presented at ... place virtually on May 29th, 2020. Dr. Benedito Carneiro, Brown University’s principal investigator ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... background and medical screening, announces the launch of a testing service aimed ... safe. The new service is provided by ClearStar’s Medical Information Services (“MIS”) ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... 23, 2020 , ... Kerafast Inc. , developers of ... the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, ... SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals Inc., announced today ... 22-24 during the American Association for Cancer Research Virtual meeting. One poster describes ... consistent single agent activity in KEAP1 mutant tumor models of NSCLC. ...
(Date:6/11/2020)... ... , ... Greffex, a leading genetic engineering company, with the ... vectors, recently announced a key manufacturing agreement with FUJIFILM Diosynth Biotechnologies to produce ... successful gene therapy delivery vehicle (vector) with broad applications for delivering treatments including ...
(Date:6/11/2020)... ... 2020 , ... Reducing carbon emissions has been and will continue to be ... market dips, ways to reduce CO2 is something we can’t avoid. , To ... biofuels being produced today are created from recycled cooking oil or crops. Unfortunately, these ...
Breaking Biology Technology:
Cached News: